BACKGROUND: Helicobacter pylori may be found during upper gastrointestinal endoscopy (UGE) performed to diagnose celiac disease (CeD), inflammatory bowel disease (IBD), and eosinophilic esophagitis (EoE). We aimed to describe the frequency of H. pylori in children undergoing UGE for CeD, IBD, and EoE and the number of children receiving eradication treatment. MATERIALS AND METHODS: A retrospective multicenter study from 14 countries included pediatric patients diagnosed with CeD, IBD, and EoE between January 2019 and December 2021. DATA COLLECTED: age, gender, hematologic parameters, endoscopic, histologic, and H. pylori culture results, and information on eradication treatment. RESULTS: H. pylori was identified in 349/3890 (9%) children [167 (48%) male, median 12 years (interquartile range 8.1-14.6)]. H. pylori was present in 10% (173/1733) CeD, 8.5% (110/1292) IBD and 7.6% (66/865) EoE patients (p = NS). The prevalence differed significantly between Europe (Eastern 5.2% (28/536), Southern 3.8% (78/2032), Western 5.6% (28/513)) and the Middle East 26.6% (215/809) [odds ratio (OR) 7.96 95% confidence interval (CI) (6.31-10.1) p < 0.0001]. Eradication treatment was prescribed in 131/349 (37.5%) patients, 34.6% CeD, 35.8% IBD, and 56.1% EoE. Predictors for recommending treatment included erosions/ulcers [OR 6.45 95% CI 3.62-11.47, p < 0.0001] and nodular gastritis [OR 2.25 95% CI 1.33-3.81, p 0.003]. Treatment rates were higher in centers with a low H. pylori prevalence (<20%) [OR 3.36 95% CI 1.47-7.66 p 0.004]. CONCLUSIONS: Identifying H. pylori incidentally during UGE performed for the most common gastrointestinal diseases varies significantly among regions but not among diseases. The indications for recommending treatment are not well defined, and less than 40% of children received treatment.
- MeSH
- celiakie * diagnóza epidemiologie MeSH
- dítě MeSH
- eozinofilní ezofagitida * epidemiologie diagnóza MeSH
- gastrointestinální endoskopie MeSH
- Helicobacter pylori * izolace a purifikace MeSH
- idiopatické střevní záněty * epidemiologie diagnóza mikrobiologie MeSH
- infekce vyvolané Helicobacter pylori * diagnóza epidemiologie farmakoterapie MeSH
- lidé MeSH
- mladiství MeSH
- předškolní dítě MeSH
- prevalence MeSH
- retrospektivní studie MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
- mladiství MeSH
- mužské pohlaví MeSH
- předškolní dítě MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- Geografické názvy
- Evropa MeSH
BACKGROUND: Inflammatory bowel disease (IBD) care and education might differ around Europe. Therefore, we conducted this European Variation In IBD PracticE suRvey (VIPER) to investigate potential differences between countries. METHODS: This trainee-initiated survey, run through SurveyMonkey®, consisted of 47 questions inquiring basic demographics, IBD training, and clinical care. Results were compared according to gross domestic product (GDP) per capita, for which countries were divided into 2 groups (low/high income, according to the World Bank). RESULTS: The online survey was completed by 1,285 participants from 40 European countries, with a majority of specialists (65.3%) working in academic institutions (50.4%). Significant differences in IBD-specific training (55.9% vs. 38.4%), as well as availability of IBD units (58.4% vs. 39.7%) and multidisciplinary meetings (73.2% vs. 40.1%), were observed between respondees from high and low GDP countries (p < 0.0001). In high GDP countries, IBD nurses are more common (85.9% vs. 36.0%), also mirrored by more nurse-led IBD clinics (40.6% vs. 13.7%; p < 0.0001). IBD dieticians (33.4% vs. 16.5%) and psychologists (16.8% vs. 7.5%) are mainly present in high GDP countries (p < 0.0001). In the current COVID era, telemedicine is available in 73.2% versus 54.1% of the high/low GDP countries, respectively (p < 0.0001). Treat-to-target approaches are implemented everywhere (85.0%), though access to biologicals and small molecules differs significantly. CONCLUSION: Much variability in IBD practice exists across Europe, with marked differences between high and low GDP countries. Further work is required to help address some of these inequalities, aiming to improve and standardize IBD care and training across Europe.
- MeSH
- biologické přípravky * MeSH
- COVID-19 * MeSH
- idiopatické střevní záněty * epidemiologie terapie MeSH
- lidé MeSH
- průzkumy a dotazníky MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- Evropa MeSH
The cost of caring for patients with inflammatory bowel disease (IBD) continues to increase worldwide. The cause is not only a steady increase in the prevalence of Crohn's disease and ulcerative colitis in both developed and newly industrialised countries, but also the chronic nature of the diseases, the need for long-term, often expensive treatments, the use of more intensive disease monitoring strategies, and the effect of the diseases on economic productivity. This Commission draws together a wide range of expertise to discuss the current costs of IBD care, the drivers of increasing costs, and how to deliver affordable care for IBD in the future. The key conclusions are that (1) increases in health-care costs must be evaluated against improved disease management and reductions in indirect costs, and (2) that overarching systems for data interoperability, registries, and big data approaches must be established for continuous assessment of effectiveness, costs, and the cost-effectiveness of care. International collaborations should be sought out to evaluate novel models of care (eg, value-based health care, including integrated health care, and participatory health-care models), as well as to improve the education and training of clinicians, patients, and policy makers.
- MeSH
- Crohnova nemoc * epidemiologie MeSH
- gastroenterologie * MeSH
- idiopatické střevní záněty * epidemiologie terapie MeSH
- lidé MeSH
- náklady na zdravotní péči MeSH
- ulcerózní kolitida * epidemiologie terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
Pediatrická manifestace zánětlivého onemocnění střev (PIBD) stále roste po celém světě a údaje se objevují i z regionů, kde PIBD nebyly dříve pozorovány.
Rates of pediatric-onset PIBD continue to rise around the world and data are emerging from regions where it was not previously reported.
- MeSH
- dítě MeSH
- idiopatické střevní záněty * epidemiologie MeSH
- lidé MeSH
- prevalence MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
- MeSH
- COVID-19 * imunologie komplikace MeSH
- idiopatické střevní záněty * epidemiologie etiologie komplikace MeSH
- lidé MeSH
- telemedicína metody MeSH
- vakcinace MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- srovnávací studie MeSH
OBJECTIVE: To describe risk factors for IBD development in a cohort of children with JIA. METHODS: JIA patients who developed IBD were identified from the international Pharmachild register. Characteristics were compared between IBD and non-IBD patients and predictors of IBD were determined using multivariable logistic regression analysis. Incidence rates of IBD events on different DMARDs were calculated, and differences between therapies were expressed as relative risks (RR). RESULTS: Out of 8942 patients, 48 (0.54% ) developed IBD. These were more often male (47.9% vs 32.0%) and HLA-B27 positive (38.2% vs 21.0%) and older at JIA onset (median 8.94 vs 5.33 years) than patients without IBD development. They also had more often a family history of autoimmune disease (42.6% vs 24.4%) and enthesitis-related arthritis (39.6% vs 10.8%). The strongest predictors of IBD on multivariable analysis were enthesitis-related arthritis [odds ratio (OR): 3.68, 95% CI: 1.41, 9.40] and a family history of autoimmune disease (OR: 2.27, 95% CI: 1.12, 4.54). Compared with methotrexate monotherapy, the incidence of IBD on etanercept monotherapy (RR: 7.69, 95% CI: 1.99, 29.74), etanercept with methotrexate (RR: 5.70, 95% CI: 1.42, 22.77) and infliximab (RR: 7.61, 95% CI: 1.27, 45.57) therapy was significantly higher. Incidence on adalimumab was not significantly different (RR: 1.45, 95% CI: 0.15, 13.89). CONCLUSION: IBD in JIA was associated with enthesitis-related arthritis and a family history of autoimmune disease. An increased IBD incidence was observed for etanercept therapy regardless of concomitant methotrexate use.
- MeSH
- antirevmatika * škodlivé účinky MeSH
- dítě MeSH
- etanercept škodlivé účinky MeSH
- idiopatické střevní záněty * farmakoterapie epidemiologie MeSH
- incidence MeSH
- juvenilní artritida * farmakoterapie epidemiologie MeSH
- lidé MeSH
- methotrexát terapeutické užití MeSH
- registrace MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
- mužské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Nespecifické střevní záněty (IBD) jsou skupinou zánětlivých onemocnění postihujících zažívací trakt. Incidence a prevalence IBD v dětství jsou na vzestupu. IBD se klasifikují na Crohnovu chorobu (CD) a ulcerózní kolitidu (UC). Speciální jednotky tvoří IBD u dětí mladších 6 let (VEO-IBD) a IBD s nediferencovaným postižením tlustého střeva (IBD-U). Etiologie IBD je multifaktoriální a není dosud plně objasněna. Genetické predispozice, alterace střevní mikrobioty, dieta a faktory životního prostředí v ní zcela jistě hrají roli. Klinické projevy CD se odvíjí od lokalizace postižení a obvykle se skládají z bolestí břicha, nauzey, zvracení, průjmů s/bez příměsi krve a hubnutí. U UC jsou typicky bolesti břicha s imperativními defekacemi průjmovitých stolic s makroskopickou příměsí krve. Stanovení diagnózy IBD je postaveno na anamnéze, fyzikálním vyšetření, laboratorních nálezech a zobrazovacích metodách, zejména endoskopiích.
Inflammatory bowel disease (IBD) is a group of inflammatory illnesses affecting the gastrointestinal tract. The incidence and prevalence of paediatric IBD is on the rise. IBD is classified into Crohn's disease (CD) and Ulcerative colitis (UC). Special subunits consist of IBD affecting children younger than 6 years of age (VEO-IBD) and undifferentiated affection of the colon (IBD-U). IBD aetiology is multifactorial and still not fully understood. Genetic predisposition, alterations of gut microbiota, diet and environmental factors play a role in its development. Clinical manifestations of CD depend on disease location, and they usually consist of abdominal pain, nausea, vomiting, diarrhoea with/out blood and weight loss. UC presents with abdominal pain and imperative defecations of bloody diarrheal stools. Establishing IBD diagnosis is based on careful history, thorough physical examination, laboratory work and imaging methods, mainly endoscopies.
- MeSH
- Crohnova nemoc diagnóza epidemiologie etiologie MeSH
- diagnostické zobrazování metody MeSH
- dítě MeSH
- endoskopie trávicího systému metody MeSH
- idiopatické střevní záněty * diagnóza epidemiologie etiologie MeSH
- kapslová endoskopie metody MeSH
- lidé MeSH
- magnetická rezonanční tomografie metody MeSH
- ulcerózní kolitida diagnóza epidemiologie etiologie MeSH
- ultrasonografie metody MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
- Publikační typ
- přehledy MeSH
The human gut microbiota consists of bacteria, archaea, fungi, and viruses. It is a dynamic ecosystem shaped by several factors that play an essential role in both healthy and diseased states of humans. A disturbance of the gut microbiota, also termed "dysbiosis", is associated with increased host susceptibility to a range of diseases. Because of splanchnic ischemia, exposure to antibiotics, and/or the underlying disease, critically ill patients loose 90% of the commensal organisms in their gut within hours after the insult. This is followed by a rapid overgrowth of potentially pathogenic and pro-inflammatory bacteria that alter metabolic, immune, and even neurocognitive functions and that turn the gut into the driver of systemic inflammation and multiorgan failure. Indeed, restoring healthy microbiota by means of fecal microbiota transplantation (FMT) in the critically ill is an attractive and plausible concept in intensive care. Nonetheless, available data from controlled studies are limited to probiotics and FMT for severe C. difficile infection or severe inflammatory bowel disease. Case series and observational trials have generated hypotheses that FMT might be feasible and safe in immunocompromised patients, refractory sepsis, or severe antibiotic-associated diarrhea in ICU. There is a burning need to test these hypotheses in randomized controlled trials powered for the determination of patient-centered outcomes.
- MeSH
- dysbióza epidemiologie mikrobiologie terapie MeSH
- feces mikrobiologie MeSH
- fekální transplantace metody MeSH
- idiopatické střevní záněty epidemiologie mikrobiologie terapie MeSH
- kritický stav epidemiologie MeSH
- lidé MeSH
- průjem epidemiologie mikrobiologie terapie MeSH
- střevní mikroflóra genetika MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
BACKGROUND AND AIMS: Recurrent primary sclerosing cholangitis (rPSC) following liver transplant (LT) has a negative impact on graft and patient survival; little is known about risk factors for rPSC or disease course in children. APPROACH AND RESULTS: We retrospectively evaluated risk factors for rPSC in 140 children from the Pediatric PSC Consortium, a multicenter international registry. Recipients underwent LT for PSC and had >90 days of follow-up. The primary outcome, rPSC, was defined using Graziadei criteria. Median follow-up after LT was 3 years (interquartile range 1.1-6.1). rPSC occurred in 36 children, representing 10% and 27% of the subjects at 2 years and 5 years following LT, respectively. Subjects with rPSC were younger at LT (12.9 vs. 16.2 years), had faster progression from PSC diagnosis to LT (2.5 vs. 4.1 years), and had higher alanine aminotransferase (112 vs. 66 IU/L) at LT (all P < 0.01). Inflammatory bowel disease was more prevalent in the rPSC group (86% vs. 66%; P = 0.025). After LT, rPSC subjects had more episodes of biopsy-proved acute rejection (mean 3 vs. 1; P < 0.001), and higher prevalence of steroid-refractory rejection (41% vs. 20%; P = 0.04). In those with rPSC, 43% developed complications of portal hypertension, were relisted for LT, or died within 2 years of the diagnosis. Mortality was higher in the rPSC group (11.1% vs. 2.9%; P = 0.05). CONCLUSIONS: The incidence of rPSC in this cohort was higher than previously reported, and was associated with increased morbidity and mortality. Patients with rPSC appeared to have a more aggressive, immune-reactive phenotype. These findings underscore the need to understand the immune mechanisms of rPSC, to lay the foundation for developing new therapies and improve outcomes in this challenging population.
- MeSH
- alanintransaminasa krev MeSH
- aspartátaminotransferasy krev MeSH
- časové faktory MeSH
- dítě MeSH
- gama-glutamyltransferasa krev MeSH
- glukokortikoidy terapeutické užití MeSH
- idiopatické střevní záněty epidemiologie MeSH
- internacionalita MeSH
- léková rezistence MeSH
- lidé MeSH
- mladiství MeSH
- portální hypertenze epidemiologie patofyziologie MeSH
- přežívání štěpu MeSH
- progrese nemoci MeSH
- recidiva MeSH
- registrace MeSH
- rejekce štěpu farmakoterapie epidemiologie patologie MeSH
- rizikové faktory MeSH
- sklerozující cholangitida krev epidemiologie chirurgie MeSH
- transplantace jater * MeSH
- věkové faktory MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
- mladiství MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- pozorovací studie MeSH
- práce podpořená grantem MeSH
- Research Support, N.I.H., Extramural MeSH
BACKGROUND: Stress has been suggested to play a potential role in inflammatory bowel disease (IBD) pathogenesis, but studies focussing on the occurrence of specific life stress events among IBD patients are scarce. Therefore, the aim of the present study was to explore the association between various life stress events and IBD. METHODS: Patients with IBD (N = 98, mean age: 38.45, 54.1% men) were compared to a group of healthy controls (N = 405, mean age: 36.45, 58.0% men) originating from a health survey conducted on a representative population sample of Czech adults. The Life Stressor Checklist-Revised (LSC-R) was used to assess the stressors. RESULTS: IBD patients had higher odds of reporting life stressors overall (p < 0.001), life stressors before the age of 16 (p < 0.004) and a higher score in traumatic stress (p < 0.005) and interpersonal violence (p < 0.001) when compared to the control group. Gender- and diagnosis-related differences are discussed. CONCLUSION: Reporting life stressors experienced during childhood or adulthood is strongly associated with IBD. This should be considered in illness management, especially in a severe course of IBD.
- MeSH
- Crohnova nemoc * MeSH
- dítě MeSH
- dospělí MeSH
- idiopatické střevní záněty * epidemiologie MeSH
- kontrolní skupiny MeSH
- lidé MeSH
- ulcerózní kolitida * MeSH
- Check Tag
- dítě MeSH
- dospělí MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Česká republika MeSH